Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 2 1

Status

Completed 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Classical hematology 3

Conditions

Venous Thrombosis 3Venous Thromboembolism 3Neoplasms 3Pancreatic Neoplasms 2Venous Thormboembolism 1Thrombosis 1Thromboembolism 1Stroke 1Soft Tissue Neoplasms 1Sarcoma 1Pulmonary Embolism 1Ovarian Neoplasms 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Catheter-Related Infections 1Carcinoma, Pancreatic Ductal 1

Interventions

Dalteparin 7apixaban 5Enoxaparin 3edoxaban 2Rivaroxaban 2Aspirin 2betrixaban 1Warfarin 1Platelet Transfusion 1Heparin, Low-Molecular-Weight 1Fondaparinux 1Dabigatran 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Venous Thromboembolism × Enoxaparin × Clear all
NCT02744092 2023-10-03

CANVAS

Alliance Foundation Trials, LLC.

Phase NA Completed
811 enrolled 19 charts
Classical hematology

Neoplasms, Pulmonary Embolism, Thrombosis, Venous Thrombosis, Venous Thromboembolism

NCT01583218 2023-08-07

APEX

Alexion Pharmaceuticals, Inc.

Phase 3 Completed
7,513 enrolled 18 charts 1 FDA
Classical hematology

Venous Thromboembolism

NCT02366871 2020-03-31

Oral Apixaban (Eliquis) Versus Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy

University of Colorado, Denver

Phase 2 Completed
400 enrolled 16 charts
Classical hematology

Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡